Posts

Month of Achievement: April 2026

Groundbreaking Advances in Prostate Cancer Diagnosis and Treatment IPCSG Newsletter Feature Introduction: A Pivotal Month for Prostate Cancer Care April 2026 has brought remarkable progress in prostate cancer care, marked by major clinical trial results, FDA-supported initiatives, and technological breakthroughs that promise to reshape how men with prostate cancer are diagnosed and treated. From minimally invasive focal therapies to breakthrough immunotherapies, and from artificial intelligence-powered diagnostics to revolutionary combination approaches, this month exemplifies the accelerating pace of innovation in oncology. For the Informed Prostate Cancer Support Group community, understanding these developments is essential—they represent options that may soon be available at major cancer centers, including UC San Diego Moores Cancer Center. The CAPTAIN Trial: Minimally Invasive Therapy Shows Promise One of April 2026's most significant announcements came...
Post a Comment
Read more

IPCSG Newsletter 2026 April

Image
ASK ME ANYTHING - YouTube  Advances in Prostate Cancer Diagnosis and Treatment: Insights from Dr. McCay's Annual Summit Presentation Overview This year's Informed Prostate Cancer Support Group annual summit featured an extended question-and-answer session with Dr. McCay, Medical Oncologist and Director of Clinical Studies Sciences at UC San Diego's Moores Cancer Center. Rather than a formal lecture, Dr. McCay opened the floor to our community, allowing participants to ask directly about their concerns—a format that proved invaluable for addressing the nuances of prostate cancer care. The following summary captures the key themes and emerging opportunities discussed, organized for patient accessibility. PSMA PET Imaging: A Game-Changer in Detection and Staging One of the most significant advances in prostate cancer management has been the FDA approval and clinical integration of PSMA-PET imaging. Unlike older imaging methods such as bone scans and CT ...
Post a Comment
Read more

Actinium-225 Theranostics for Advanced Prostate Cancer:

Image
 A Patient's Guide to the State of the Science An IPCSG patient-education feature — April 2026 BLUF (Bottom Line Up Front):   Actinium-225 (Ac-225) PSMA-targeted alpha therapy is producing some of the most striking PSA response numbers ever seen in heavily pretreated mCRPC — about 65% of men achieve a PSA50 response across pooled studies, a figure that exceeds what beta-emitting Lu-177 PSMA delivers in the same setting. It is showing meaningful activity even in men who have already progressed through Pluvicto (Lu-177 PSMA-617). However, Ac-225 PSMA therapy is not a finished product: it remains investigational only — no Ac-225 drug has FDA approval for prostate cancer as of April 2026 — and the dominant problem is severe, often permanent, dry mouth (xerostomia) from off-target damage to the salivary glands, which is reported in roughly 80–85% of treated patients. A wave of randomized phase 2/3 trials (PSMAcTION, CONVERGE-01, AcTION, TATCIST, ACCEL, AlphaBreak...
Post a Comment
Read more